Clinical Trials

Leaders in C3 targeted therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. 

Visit clinicaltrials.gov to learn more about ongoing studies, study participation including eligibility, the informed consent process, questions to ask when considering study participation. 

If you have questions about our clinical trials, please email us at clinicaltrials@apellis.com. Learn more about ongoing, Apellis sponsored clinical trials below. 

_{Sobi has global co-development and ex-U.S. commercialization rights for systemic pegcetacoplan.}